Physician profile
Steven D Rock
NPI 1407851587
$3,048.55
in general payments reported to CMS, 2019-2025
33 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $124 · 2021: $183 · 2022: $517 · 2023: $659 · 2024: $663 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,509.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $375.25 | 2019-2025 | Provenge |
| Astellas Pharma US INC | $345.10 | 2019-2024 | Xtandi, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $327.69 | 2019-2024 | |
| Urogen Pharma, INC. | $222.44 | 2022-2024 | Jelmyto |
| Pfizer INC. | $202.87 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $201.06 | 2023-2025 | Gemtesa |
| Abbvie INC. | $196.90 | 2019-2024 | |
| Axonics, INC. | $123.53 | 2022-2024 | Axonics |
| Janssen Biotech, INC. | $120.08 | 2019-2024 | Erleada, Akeega |
| Baxter Healthcare | $94.53 | 2024 | Tisseel |
| Myovant Sciences INC. | $76.40 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $68.71 | 2020-2021 | |
| Coloplast Corp | $67.66 | 2023 | Titan |
| Boston Scientific Corporation | $65.82 | 2019-2023 | Lithovue |
| Endo Pharmaceuticals INC. | $64.77 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $59.00 | 2024 | Xt Cdx |
| Accord Healthcare, INC. | $45.77 | 2023 | |
| Ferring Pharmaceuticals INC. | $43.16 | 2024 | Adstiladrin |
| Avadel Specialty Pharmaceuticals, LLC | $33.68 | 2019 | |
| Shire North American Group INC | $33.28 | 2019 | |
| Verity Pharmaceuticals INC. | $32.16 | 2023 | Trelstar |
| Palette Life Sciences, INC. | $31.46 | 2022 | |
| Progenics Pharmaceuticals, INC. | $26.31 | 2023 | Pylarify |
| Urovant Sciences INC | $25.15 | 2021 | |
| Blue Earth Diagnostics | $24.70 | 2023 | |
| Allergan, INC. | $20.88 | 2019 | |
| Olympus America INC. | $20.32 | 2025 | Tecoflex |
| Zyla Life Sciences, INC. | $19.86 | 2020 | |
| Amgen INC. | $18.69 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.14 | 2020 | |
| Myriad Genetic Laboratories, INC. | $16.81 | 2023 | Prolaris |
| Laborie Medical Technologies Corp. | $13.26 | 2022 | |
| Immunitybio, INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Rock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.